Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
NCT ID: NCT01603082
Last Updated: 2015-12-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
343 participants
INTERVENTIONAL
2012-07-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ticagrelor
Ticagrelor - 180 mg loading dose
Ticagrelor
180 mg loading dose
Clopidogrel
Clopidogrel - 600 mg loading dose
Clopidogrel
600 mg loading dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ticagrelor
180 mg loading dose
Clopidogrel
600 mg loading dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female patients aged 18 years or older
* Documented acute coronary syndrome and troponin negative and undergoing Ad Hoc percutaneous coronary intervention (PCI)
* Females must be post menopausal or surgically sterile
* Taking aspirin as an anti-platelet medication
Exclusion Criteria
* Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve)
* Contraindication that ticagrelor or clopidogrel should not be administered Patient requires dialysis
* History of intolerance or allergy to aspirin
18 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Glenn F. Carlson, MD
Role: STUDY_DIRECTOR
AstraZeneca Pharmaceuticals, Wilmington, DE 19850-5437 USA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Birmingham, Alabama, United States
Research Site
San Francisco, California, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Jacksonville, Florida, United States
Research Site
Ypsilanti, Michigan, United States
Research Site
Minneapolis, Minnesota, United States
Research Site
Tupelo, Mississippi, United States
Research Site
North Kansas City, Missouri, United States
Research Site
Belleville, New Jersey, United States
Research Site
New York, New York, United States
Research Site
The Bronx, New York, United States
Research Site
Greensboro, North Carolina, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Tyler, Texas, United States
Research Site
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sweeny JM, Angiolillo DJ, Franchi F, Rollini F, Waksman R, Raveendran G, Dangas G, Khan ND, Carlson GF, Zhao Y, Teng R, Mehran R. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. J Am Heart Assoc. 2017 Mar 29;6(4):e005650. doi: 10.1161/JAHA.117.005650.
Angiolillo DJ, Franchi F, Waksman R, Sweeny JM, Raveendran G, Teng R, Zhao Y, Carlson G, Khan N, Mehran R. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. J Am Coll Cardiol. 2016 Feb 16;67(6):603-613. doi: 10.1016/j.jacc.2015.11.044.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5130L00014
Identifier Type: -
Identifier Source: org_study_id